Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration

Indian Journal of Ophthalmology

Volumn 55, Issue 6, 2007, Pages 431-435

  Gopal, Lekha ^a,b   Sharma, Tarun ^a  

^a VISION RESEARCH FOUNDATION   (India)

^b SANKARA NETHRALAYA   (India)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Intravitreal steroid

Indexed keywords

EID: 35549009732     PISSN: 03014738     EISSN: 03014738     Source Type: Journal    
DOI: 10.4103/0301-4738.36477     Document Type: Conference Paper

References (35)

1. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-45.
2. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalomol 2001;1331:541-60.
3. Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamrinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 2004;138:1046-8.
4. Penfold PL, Wen Li, Madigen MC, King NJ, Provis JM. Modulation of permeability and adhesion molocule epxression by human choroidal endothelail cells. Invest Ophthalmol Vis Sci 2002;43:3125-30.
5. Wang YS, Friedrichs U, Eider W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF- induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 2002;240:42-8.
6. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Opthalmol 2001;119:399-404.
7. Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, D'Amico DJ, Flynn HW Jr, et al. Evolving guidelines for intravitreousl injections. Retina 2004;24:S3-19.
8. Vedantham V, Kim R. Intravitreal injection of triamcinolone acetonide for diabetic macular edema: Principles and practice. Indian J Ophthalmol 2006;54:133-7.
9. Nishimura A, Kokayashi A, Segawa Y, Sakurai M, Shirao E, Shirao Y, et al. Isolating triamcinolone acetonide particles for intravitreal use with a porous membrane filter. Refina 2003;23:777-9.
10. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after inrtavitreal triamrinolone acetonide injection. Ophthalmology 2005;112:593-8.
11. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamdnolone. A pilot study. Aust N Z J Ophthalmol 1995;23:293-8.
12. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal traimcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998;26:277-81.
13. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamdnolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-50.
14. Ranson NT, Danis RP, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 2002;86:527-9.
15. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: One-year results. Arch Ophthalmol 2003;121:667-73.
16. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003;87:462-8.
17. Jonas JB, Kreissig I, Degenring R, Friedemann T, Akkoyun I. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye 2005;19:153-70.
18. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004;122:218-22.
19. Jonas JB, Spandau UH, Harder B, Vossmerbaeumer U, Kamppeter BA. Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2006;141:228.
20. Schmidt-Erfurth U, Schotzen-Schrehardu, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of Photodynamic therapy on expression of Vascular endothelial growth factor, Vascular endothelial growth factor receptor 3 and Pigment epithelial- growth factor. Invest Opthalmol Ws Sci 2003;44:4473-80.
21. Lai TY, Chan WM, Lam DS. Transient reduction in retinal function revealed by multifocal electroretinogram following photodynamic therapy. Am J Ophthalmol 2004;137:826-33.
22. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamdnolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-25.
23. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Opthalmol 2004;88:344-7.
24. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22.
25. Nicolo M, Ghiglione D, Lai S, Nasciuti F, Cicinelli S, Calabria G. Occult with no classic choroidal neovascularization secondary to agerelated macular degeneration treated by intravitreal triamdnolone and photodynamic therapy with verteporfin. Retina 2006;26:58-64.
26. Chan WM, Lai TY, Wong AL, Tong JP, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: A comparative study. Br J Ophthalmol 2006;90:337-41.
27. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;141:638-45.
28. Ergun E, Maar N, Ansari-Shahrezaei S, Wimpissinger B, Krepler K, Wedrich A, et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol 2006;142:10-6.
29. Ruiz-Moreno JM, Montero JA, Barile S, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina 2006;26:602-12.
30. Arias L, Garria-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology 2006;113:2243-50.
31. Axer-Siegel R, Ehrlich R, Avisar I, Kramerr M, Rosenblatt I, Priel E, et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neovascular age-related macular degeneration with pigment epithelium detachment. Ophthalmic Surg Lasers Imaging 2006;37:455-61.
32. Hussain N, Das T, Rawal H, Kallukuri SB, Mohan Ram LS, Khanna R. Combination therapy of intravitreal triamcinolone and photodynamic therapy with verteporfin for subfoveal choroidal neovascularization. Indian ] Ophthalmol 2006;54:247-50.
33. Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, et al. Acute endophthalmitis following intravitreal triamdnolone acetonide injection. Am J Opthalmol 2003;136:791-6.
34. Jonas JB, Krdssig L Degenring RF. Cataract surgery after intravitreal injection of triamcinolone acetonide. Eye 2004;18:361-4.
35. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM. Intravitreal triamdnolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005;112:139-43.